BACKGROUND: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care. METHODS: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014. They estimated 5-year relative survival at the time of diagnosis and at each additional year survived up to 25 years after diagnosis, conditional on the individual being alive at the beginning of that year. RESULTS: A total of 205,954 AYA patients with cancer were identified. Thyroid cancer, melanoma, testicular cancer, breast cancer, lymphoma, leukemia, and central nervous system (CNS) tumors comprised 67% of all cancers. For all cancers combined, 5-year relative survival was 84.5% (95% confidence interval, 84.3%-84.7%) at 1 year after diagnosis and 94.0% (95% CI, 93.9%-94.2%) at 5 years. The relative survival first exceeded 95%, reflecting minimal excess mortality compared with the general population, at 7 years. Patients with thyroid cancer, testicular cancer, melanoma, and breast cancer reached a relative survival of >95% at the time of diagnosis and at 1, 3, and 18 years after diagnosis, respectively. Estimates for those with Hodgkin lymphoma and leukemia were >95% at 6 and 13 years, respectively, but declined to <95% at 20 years. AYA individuals with CNS tumors did not reach 95% by 25 years after diagnosis. CONCLUSIONS: For AYA survivors of breast cancer, CNS tumors, and hematologic malignancies, long-term excess mortality should be considered when planning follow-up care. Cancer 2018;124:3037-43. V C 2018 American Cancer Society.
INTRODUCTION
More than 70,000 adolescents and young adults (AYAs; those aged 15-39 years) are diagnosed with cancer each year in the United States. 1 Although considerable variability exists according to cancer site and stage of disease, the 5-year relative survival at the time of diagnosis has been estimated at >80% for all AYA patients with cancer combined. 2 Extensive survivorship research in recent decades has focused on patients diagnosed with cancer as children and older adults, yet few studies to date have reported outcomes specifically for patients diagnosed as AYAs. With the majority of AYA patients with cancer expected to become long-term survivors, there is a critical need for research efforts to inform the survivorship care of this growing population.
Estimates of conditional survival represent clinically useful measures for patients with cancer and their physicians when planning appropriate follow-up care after initial cancer treatment, and provide survivors with relevant indicators of prognosis at various stages of survivorship. Conditional survival is the probability of surviving for a specified time interval, given that one already has survived a certain length of time after a cancer diagnosis, and, when plotted over time, reflects the changing risk of death with increasing time since diagnosis. Examining conditional survival among patients with cancer compared with expected survival among comparable groups in the general population can reveal excess mortality remaining among patients with cancer at a given point after diagnosis. Excess mortality, identified by a conditional relative survival of <100%, may reflect death from cancer recurrences, second primary cancers, or treatment-related late effects. Long-term conditional relative survival estimates have been published for various cancer sites, particularly those most common in older adults, [3] [4] [5] [6] [7] [8] but to our knowledge have not been reported specifically among AYAs with cancer. Using population-based data from the Surveillance, Epidemiology, and End Results (SEER) program, the objective of the current study was to estimate 5-year relative survival for AYA patients with cancer at the time of diagnosis and for each additional year survived (ie, conditional 5-year relative survival) up to 25 years after diagnosis.
MATERIALS AND METHODS
Using the SEER 9 database, 9 we identified all patients diagnosed with a cancer at ages 15 to 39 years between 1973 and 2009 and followed through 2014. We included patients diagnosed with a first primary cancer with malignant behavior. Patients diagnosed with Kaposi sarcoma, those diagnosed via death certificate or autopsy only, and patients recorded as alive with no survival time were excluded. Cancer site was classified according to AYAspecific recodes of International Classification of Diseases for Oncology, third edition (ICD-O-3) site and histology codes, available through SEER. 10 For testicular cancer, which does not have an AYA-specific recode, we used the regular SEER site recode (ICD-O-3/World Health Organization 2008). We classified stage using SEER historic stage A for applicable sites. Other patient characteristics obtained from SEER included age at the time of diagnosis and sex. This study was considered exempt by the institutional review board of the University of North Carolina.
Statistical Analysis
Relative survival was calculated as the ratio of observed survival among patients with cancer to expected survival in the general population with a similar distribution with regard to age, sex, and race during the same time period. The actuarial method was used for survival calculations. General population mortality data, provided by the National Center for Health Statistics and accessed through SEER, were used to generate expected survival using the Ederer II method. 11 We estimated the 5-year relative survival among AYA patients with cancer at the time of diagnosis and for each additional year survived up to 25 years after diagnosis, conditional on the individual being alive at the beginning of that year. Relative survival estimates >100% were adjusted and are reported as 100%. Estimates were generated for all cancer sites combined, and for selected common cancers diagnosed among AYA individuals. We also reported the years at which conditional relative survival exceeded 90% and 95%, which we considered to reflect little and minimal excess mortality, respectively. 3 In subgroup analyses, we examined sitespecific estimates according to year of diagnosis, sex, age at the time of diagnosis, and stage of disease. Patients with distant-stage disease were excluded from analyses according to stage due to small numbers with extended followup for the majority of cancer sites. Analyses were performed using SEER*Stat (version 8.3.4; National Cancer Institute, Bethesda, Maryland). Table 1 ). Relative survival first exceeded 95%, reflecting minimal excess mortality, by 7 years after diagnosis. Patients with thyroid and testicular cancers demonstrated a 5-year relative survival >95% beginning at the time of diagnosis and at 1 year, respectively, whereas those with melanoma and cervical/uterine cancers reached > 95% by 3 years. Relative survival increased rapidly for patients with colorectal cancer, from 69.9% at 1 year to 97.0% at 10 years. In contrast, gains were more gradual for female breast cancer, with a >95% relative survival not achieved until 18 years after diagnosis. Estimates exceeded 95% by 7 years for patients with soft-tissue sarcomas, and 9 years for those with non-Hodgkin lymphoma. Those for patients with Hodgkin lymphoma and leukemia were >95% at 6 and 13 years, respectively, but were slightly less than 95% at 20 years. Across types of leukemia, a 95% relative survival was exceeded at 8 years for patients with acute lymphoid leukemia and at 9 years for those with acute myeloid leukemia, but was not achieved by 25 years after diagnosis for those with chronic myeloid leukemia (data not shown). For patients with CNS tumors, 5-year relative survival did not exceed 90% by 25 years after diagnosis. In analyses according to year of diagnosis, relative survival generally was greater for patients diagnosed between 1988 and 2009 compared with those diagnosed during 1973 through 1987. Improvements over time were observed for the majority of cancer types, but were especially apparent for leukemias, female breast cancer, lymphomas, and CNS tumors within the first 10 years of diagnosis.
RESULTS
For the majority of cancer sites, including melanoma, non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia, colorectal cancer, and soft-tissue sarcomas, conditional relative survival estimates were somewhat better for females than males, particularly in the years closest to diagnosis (see Supporting Table 2 ). Estimates generally were similar according to age at diagnosis, but were consistently slightly higher among those aged 15 to 29 years compared with those aged 30 to 39 years ( 
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Cancer pattern was observed for female breast cancer, with slightly higher estimates for patients diagnosed at ages 30 to 39 years, although differences between age groups appeared negligible by approximately 7 years after diagnosis. For colorectal cancer and soft-tissue sarcomas, the 5-year relative survival estimates among patients with regional stage disease approached those among patients with localized disease by or before 10 years after diagnosis (Fig. 2 ) (see Supporting Table 4 ). Estimates for patients with regional stage melanoma and cervical/uterine cancers exceeded 95% before 10 years, but remained slightly lower than estimates for patients with localized disease throughout the study period. Among women with regional stage breast cancer, 5-year relative survival remained consistently lower than among those with localized stage, and did not exceed 95% by 25 years after diagnosis.
DISCUSSION
In the current study, we examined conditional relative survival up to 25 years after diagnosis among AYA patients with cancer, an understudied patient subgroup with respect to long-term health outcomes. For all cancer types combined, 5-year relative survival exceeded 95% by 7 years after diagnosis, suggesting minimal excess mortality beyond this point, and there was some evidence of a survival improvement over time. However, for specific cancer types, including CNS tumors, female breast cancer, Hodgkin lymphoma, and leukemia, the current analyses suggested evidence of excess mortality risk that persisted, or re-emerged, >10 years after a cancer diagnosis. In recent years, AYA patients with cancer have increasingly been distinguished from pediatric and older adult patients with cancer with regard to their cancer type distribution, disease biology, treatment efficacy, and psychosocial barriers to care, and short-term relative survival estimates among AYA patients have been reported. 2, 12 However, little research exists to inform the follow-up care of AYA individuals who already have survived several years beyond diagnosis. Potential contributors to excess mortality among long-term cancer survivors include cancer recurrences, second primary malignancies, and noncancer treatment-related late effects, but to our knowledge long-term survival measures among AYA patients with cancer have rarely been described.
Although our overall analyses indicated minimal survival deficits for AYA patients with cancer 7 years after diagnosis, patterns of relative survival gains over time were not uniform across cancer types. Much of the high relative survival noted close to diagnosis was driven by a few cancer types, particularly thyroid and testicular cancers, with both high incidence and high survival in this age group. Cervical/uterine cancers and melanoma also quickly achieved a relative survival >95%, although other cancer types still exhibited some excess mortality beyond 5 years after diagnosis.
The slight decline in relative survival observed after 10 years among patients with Hodgkin lymphoma is noteworthy, and may largely reflect late effects of cancer treatment in this population. 13 In the modern era of radiotherapy and chemotherapy, Hodgkin lymphoma is generally considered a curable malignancy, with relatively high survival in the years immediately after diagnosis. 13 However, studies have consistently documented significantly elevated risks of second cancers and cardiovascular disease among survivors of Hodgkin lymphoma, with 3-fold to 6-fold increases in the risk of coronary heart disease, valvular heart disease, and heart failure, [13] [14] [15] and increases of 2-fold to >20-fold in the risk of various types of second malignancies 13, [16] [17] [18] [19] [20] [21] [22] compared with the general population. Anthracycline-based chemotherapies and mediastinal radiation have often been implicated in the development of cardiovascular disease in survivors of Hodgkin lymphoma, whereas alkylating chemotherapies and radiotherapy likely account for the majority of the excess in second cancers. 13 In the current analyses, conditional relative survival was lowest among AYA patients with CNS tumors. Although neither age group exceeded a relative survival of 95% within 25 years of diagnosis, our results demonstrated poorer long-term survival for patients diagnosed with CNS tumors at ages 30 to 39 years compared with those diagnosed at ages 15 to 29 years. Differences according to age also were apparent for AYAs with leukemia. Patients aged 15 to 29 years demonstrated minimal excess mortality 10 years after diagnosis, whereas those aged 30 to 39 years at the time of diagnosis demonstrated evidence of a slight decline in relative survival after 10 years, and remained at a relative survival of <95% at 25 years, potentially reflecting differences in pediatric versus adult treatment regimens for leukemia. 23, 24 These findings are informative for comparison with prior studies of longterm outcomes among childhood cancer survivors (those diagnosed at age <21 years), which have reported somewhat higher survival at 20 years after diagnosis for patients with CNS tumors and leukemia compared with what we observed in older AYA cancer patients. 25 The results of the current study further highlight the critical importance of long-term surveillance for patients diagnosed with these malignancies at the upper end of the AYA age range.
For all stages of disease combined, 5-year relative survival in AYA patients with breast cancer remained <95% until 18 years after diagnosis. Although differences according to stage of disease decreased over time, women with regional breast cancer continued to have poorer survival than those with localized breast cancer up to 25 years after diagnosis. Late recurrences, even 10 to 20 years after diagnosis, are likely contributors to the slower gains in relative survival noted among patients with breast cancer, particularly in those with hormone receptor-positive tumors. 26 However, the risk of a second primary cancer also is increased among younger survivors of breast cancer, 27 and several studies have suggested elevated cardiovascular morbidity and mortality among women with a breast cancer history, especially those treated with radiation before the 1980s or with high doses of anthracyclinebased chemotherapies. [28] [29] [30] [31] [32] The continued follow-up of patients treated in the last 2 to 3 decades will be needed to gauge how the recent evolution of therapies for breast cancer, including improvements in radiation techniques, 33 the decreased use of anthracyclines, 34 and the introduction of trastuzumab for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancers, 35 will affect long-term relative survival in AYA patients.
The strengths of the current study include the long follow-up period and the large cohort of AYA patients from population-based cancer registries across the United States. This study also has limitations to consider. Information regarding disease recurrence is not available in registry data, but would help to further stratify patients for the evaluation of conditional survival estimates. Detailed information regarding cancer treatments also would be informative for assessing the potential impact of treatment-related late effects on long-term survival, but is not captured in SEER. Finally, recent changes in cancer treatments would not be reflected in the current study estimates of relative survival at 20 years after diagnosis because these analyses were necessarily restricted to patients diagnosed in the 1970s and 1980s. Further research will be needed to monitor trends in long-term conditional survival for AYA patients diagnosed in more recent years.
Overall, the results of the current analyses suggest that the majority of AYA patients with cancer who have survived at least 7 years after diagnosis will experience little difference in survival from that of the general population. However, for patients with cancer types such as leukemia, CNS tumors, Hodgkin lymphoma, and breast cancer, the potential for long-term excess mortality should be considered when planning follow-up care. 
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